EU approval for Gilead's Stribild for HIV-1 infection

29 May 2013

US biotech major Gilead Sciences (Nasdaq: GILD) says that the European Commission has granted marketing authorization for Stribild (elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir disoproxil (as fumarate) 245mg), a single tablet regimen for the treatment of HIV-1 infection in adults who are antiretroviral treatment-naive or are infected with HIV-1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild.

Stribild is already approved in the USA, Canada, Australia, South Korea, Japan and Turkey and first-quarter 2013 sales came in at $92.1 million (The Pharma Letter May 3). Analysts have forecast Stribild as a potential $4 billion-a-year blockbuster. Giiead also announced yesterday that Stribild is now available in the UK.

Benefits of single tablet regimen

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK